Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- United States
- Slowdown in U.S. Health Care Spending in 2005
- Solid Growth in U.S. Pharmaceutical Market in 2006
- Increased Scrutiny of Drug Prices for Federal Programs
- Continued Growth in Medicare Part D Enrollment
- Pressure for Government Price Negotiations for Medicare Part D
- Prospect of Increased Medicaid Rebates
- Measures to Improve Access to Generic Drugs
- Regulation of Biogenerics
- Drug Importation
- France
- National Frame of Reference for the Good Use of Expensive and Innovative
Drugs
- Parallel Imports
- Obesity Therapy Qualifi es for Limited Reimbursement
- GlaxoSmithKline Fined for Predatory Pricing
- Germany
- Slowdown in Pharmaceutical Spending
- New Health Care Reforms Enacted
- Growth of Manufacturer Rebates
- Daily Cost-of-Therapy Limits
- Italy
- Concern over Regional Reference Pricing Initiatives
- Industry Calls for a Change in Pharmaceutical Policy
- Spain
- Implementation of New Reference Pricing System
- New System to Monitor Parallel Exports
- United Kingdom
- Proposal to Replace the Pharmaceutical Price Regulation Scheme
- New Candidates for Single Technology Appraisals
- Adjustments to Prescription Charges
- Japan
- Expected Reform of the Pricing and Reimbursement System
- Limited Level of Generics Substitution
- Outlook and Implications for the Pharmaceutical Industry
Figures
- 1. Evolution of Prescription Drug Expenditures in the United States in
Select Years from 1970 to 2005
- 2. Main Sources of Funding for U.S. Prescription Drug Expenditures, 2005
- 3. Medicare Benefi ciaries' Prescription Drug Coverage, January 2007
|
Related Report
|
View Cart
